Phase 1 Study of OSI-930 in Cancer Patients
Open label, phase 1, dose escalation
Advanced Solid Tumors
DRUG: OSI-930|DRUG: OSI-930
Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930, 2.5 years
Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity, 2.5 years
Multicenter, open-label, phase 1, dose escalation study to determine the maximum tolerated dose on both once daily (QD) and twice daily (BID) schedules.

Patients may continue to receive OSI-930 until one of the following occurs: disease progression, adverse event requiring withdrawal, failure to recover from toxicity despite a 14-day dosing interruption, medical or ethical reasons, patient request, or patient death.